EI
KRYS icon

EAM Investors’s Krystal Biotech KRYS Stock Holding History

EAM Investors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.03M Sell
16,227
-256
-2% -$76.5K 0.54% 64
2026
Q1 		$4.26M Sell
16,483
-8,184
-33% -$2.18M 0.49% 83
2025
Q4 		$6.08M Buy
+24,667
New +$5.19M 0.68% 34
2024
Q4 		– Sell
-12,858
Closed -$2.34M – 305
2024
Q3 		$2.34M Sell
12,858
-13,426
-51% -$2.59M 0.35% 134
2024
Q2 		$4.83M Sell
26,284
-151
-0.6% -$25.4K 0.78% 15
2024
Q1 		$4.7M Buy
+26,435
New +$3.67M 0.73% 22
2023
Q4 		– Sell
-16,091
Closed -$1.87M – 321
2023
Q3 		$1.87M Buy
16,091
+377
+2% +$46K 0.36% 116
2023
Q2 		$1.84M Sell
15,714
-9,013
-36% -$920K 0.34% 120
2023
Q1 		$1.98M Sell
24,727
-8,518
-26% -$669K 0.39% 111
2022
Q4 		$2.63M Sell
33,245
-194
-0.6% -$14.4K 0.55% 53
2022
Q3 		$2.33M Buy
33,439
+2,809
+9% +$203K 0.51% 73
2022
Q2 		$2.01M Sell
30,630
-3,248
-10% -$202K 0.49% 68
2022
Q1 		$2.25M Sell
33,878
-989
-3% -$61.7K 0.42% 80
2021
Q4 		$2.44M Buy
+34,867
New +$2.03M 0.4% 73
2020
Q2 		– Sell
-69,430
Closed -$3M – 288
2020
Q1 		$3M Buy
69,430
+3,967
+6% +$207K 0.93% 10
2019
Q4 		$3.63M Sell
65,463
-22,451
-26% -$1.1M 0.8% 18
2019
Q3 		$3.05M Buy
87,914
+6,467
+8% +$289K 0.81% 20
2019
Q2 		$3.28M Buy
81,447
+58,626
+257% +$1.92M 0.8% 18
2019
Q1 		$751K Sell
22,821
-10,204
-31% -$241K 0.18% 212
2018
Q4 		$686K Buy
+33,025
New +$691K 0.19% 217

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EAM Investors's KRYS Position: Q2 2026 in Review

EAM Investors reduced its Krystal Biotech (KRYS) stake by 1.6% in Q2 2026, selling an estimated $76.5K and leaving 16,227 shares worth $6.03M. The position accounts for 0.54% of the portfolio, ranked #64.

EAM Investors first reported a position in KRYS in Q4 2018 and has held it in 20 quarters since. The position peaked at $6.08M in Q4 2025. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • EAM Investors held 16,227 shares of Krystal Biotech worth $6.03M as of Q2 2026.
  • EAM Investors sold 256 Krystal Biotech shares in Q2 2026, an estimated $76.5K.
  • Krystal Biotech made up 0.54% of EAM Investors's portfolio in Q2 2026, its #64 holding.
  • EAM Investors first reported a position in Krystal Biotech in Q4 2018 and has held it in 20 quarters since.
  • EAM Investors's Krystal Biotech position peaked at $6.08M in Q4 2025.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.